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Abstract
Background: Targeted therapies based on the molecular and histological features of cancer types are becoming
standard practice. The most effective regimen in lung cancers is different between squamous cell carcinoma (SCC)
and adenocarcinoma (AD). Therefore a precise diagnosis is crucial, but this has been difficult, particularly for poorly
differentiated SCC (PDSCC) and AD without a lepidic growth component (non-lepidic AD). Biomarkers enabling a
precise diagnosis are therefore urgently needed.
Methods: Cap Analysis of Gene Expression (CAGE) is a method used to quantify promoter activities across the whole
genome by determining the 5’ ends of capped RNA molecules with next-generation sequencing. We performed CAGE
on 97 frozen tissues from surgically resected lung cancers (22 SCC and 75 AD), and confirmed the findings
by immunohistochemical analysis (IHC) in an independent group (29 SCC and 45 AD).
Results: Using the genome-wide promoter activity profiles, we confirmed that the expression of known molecular
markers used in IHC for SCC (CK5, CK6, p40 and desmoglein-3) and AD (TTF-1 and napsin A) were different between SCC
and AD. We identified two novel marker candidates, SPATS2 for SCC and ST6GALNAC1 for AD, as showing comparable
performance and complementary utility to the known markers in discriminating PDSCC and non-lepidic AD. We
subsequently confirmed their utility at the protein level by IHC in an independent group.
Conclusions: We identified two genes, SPATS2 and ST6GALNAC1, as novel complemental biomarkers discriminating
SCC and AD. These findings will contribute to a more accurate diagnosis of NSCLC, which is crucial for precision
medicine for lung cancer.
Background
Non-small cell lung cancers (NSCLCs) account for ap-
proximately 89 % of all lung cancers. NSCLCs are further
classified into adenocarcinoma (AD: 45 %), squamous cell
carcinoma (SCC: 24 %), and large cell carcinomas (3 %),
respectively [1]. Recent developments in targeted therapies,
such as pemetrexed [2] and bevacizumab [3, 4], require
precise typing of NSCLCs, since they are inappropriate for
SCC. Accurate discrimination of SCC from the remaining
NSCLCs is crucial for choosing the appropriate treatment
regimen.
SCC is defined as a malignant epithelial tumor showing
keratinization and/or intercellular bridges. These features
are evident in well differentiated (WD) tumors; however,
they are only focally present in poorly differentiated (PD)
tumors. The histological diagnosis of SCC is sometimes
difficult for PD tumors based on small biopsy or cytology
samples [5, 6]. AD is conventionally diagnosed based on
the histological characteristics of luminal formation and/
or intracytoplasmic mucin in the tumor. About 90 % of
lung ADs consist of mixed heterogeneous components,
such as lepidic, acinar, papillary, solid and micropapillary
components, where the lepidic component is easy to
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obtain as a well preserved tissue structure compared to
the other components because it is usually observed in
the peripheral area of the tumor. If a lepidic component
is found in a diagnostic material, it is easy to diagnose
an AD. However, if a tumor biopsy specimen does not
have a lepidic component, the histological diagnosis of
AD is sometimes difficult based on small biopsy or cy-
tology samples, especially when the tissue structure is
not preserved. In particular, discriminating between
PDSCC and solid predominant AD is challenging to the
pathologists based solely on the morphological findings
of tumors [5, 6].
Cellular function is implemented with a series of mol-
ecules produced by the cell. Distinct types of cells can
be discriminated at the molecular level even if they are
similar to each other morphologically. The emergence of
next-generation sequencing technologies enabled us to
obtain accurate snapshot molecules, in particular DNA
and RNA. Cap Analysis Gene Expression (CAGE) is a
genome-wide approach to sequencing only the 5’-ends of
capped RNAs [7], and its profiles represent promoter ac-
tivities based on the frequencies of transcription starting
sites (TSSs). CAGE was used to annotate functional ele-
ments within the human genome in the ENCODE project
[8], and it was used to monitor global transcriptome states
characterizing diverse cell types across the human body in
the FANTOM5 project [8–10]. Obtaining an accurate
map of transcriptome in a wide range of primary cells,
organs, and cell lines enabled us to understand a series of
observations, such as structural relationships between
cancer cell lines [11], mesothelial signatures in high-grade
serous ovarian cancer [12], and regulatory regions of the
three genes involved in Rett Syndrome [13].
The present study is the first use of CAGE to survey pri-
mary tumors for a specific clinical problem, in this case,
the identification of biomarkers enabling a precise diagno-
sis of SCC and AD. Our genome-wide survey led us to
identify two novel markers that complement known
markers to recognize a unique set of tumors. Follow-up
experiments on another group of patients confirmed their
performance for discriminating SCC from AD.
Methods
Patients enrolled for biomarker exploration by CAGE: The
discovery set
The sample collection was conducted at Juntendo
University in Japan, between February 2010 and January
2011. Under a protocol approved by the institutional
review board of Juntendo University (No.2012069), 97
tumor tissue specimens were collected after the tissue
donors provided written informed consent. In the operat-
ing room, 3–5 mm3 cubes of fresh lung cancer tissue were
dissected and immediately placed in 1.0 ml of RNAlater
RNA Stabilization Reagent (Qiagen, GmbH, Germany,
Hilden) for 24–48 h at 4 °C for RNA stabilization. There-
after, the specimens were stored at −80 °C until RNA
extraction. Total RNA was extracted from the frozen
tissue sections according to the standard protocol.
The gold standard of histological diagnosis used in the
present study is based on the permanent pathological
reports made by at least two experienced pathologists in
accordance with the 2004 WHO Classification of Lung
Tumors [14]. In clinical practice, pathologists make
diagnoses based on histological criteria (presence of a
malignant epithelial tumor showing keratinization and/
or intercellular bridges for SCC and the presence of
luminal formation and/or intracytoplasmic mucin in the
tumor for AD). Immunohistochemical analysis (IHC)
such as TTF-1 or p40 is performed only in cases where a
definitive diagnosis is difficult based solely on the above-
mentioned histological criteria. If no morphological
features specific to SCC or AD were noted, tumors were
diagnosed as large cell carcinoma, and the patient was
excluded from the study cohort.
ADs were further subtyped into three groups based on
the lepidic growth component in each tumor: pure
lepidic AD, AD with a 100 % lepidic growth component;
mixed lepidic AD, AD with any lepidic component and
non-lepidic AD, AD without a lepidic component. SCCs
were also subtyped into three groups based on the
degree of keratinization and/or intercellular bridges:
WDSCC, moderately differentiated (MD) SCC and
PDSCC. The 97 frozen tumor tissues consists of 22 SCC
and 75 AD, including five cases of WDSCC, 14 MDSCC,
three PDSCC, seven pure lepidic AD, 56 mixed lepidic
AD, and 12 cases of non-lepidic AD.
Patients enrolled for biomarker validation by an IHC: The
validation set
In addition to the collection above, 74 tumors were col-
lected by surgical resection of lung cancers (SCC, n = 29;
AD, n = 45) at Juntendo University between February
2013 and November 2013 under the same protocol de-
scribed above. The 74 tumors consisted of four WDSCC,
14 MDSCC, 11 PDSCC, seven pure lepidic AD, 22
mixed lepidic AD, and 16 non-lepidic AD, which were
pathologically diagnosed using the same criteria as the
samples collected for the CAGE analysis.
CAGE assay
CAGE libraries were prepared following the previously
described protocol [15]. In brief, the total RNA extracts
were subjected to a reverse transcription reaction with
SuperScript III (Life Technologies, Carlsbad, CA, USA).
After purification using RNAclean XP (Beckman
Coulter, Brea, CA, USA), double stranded-RNA/cDNA
were oxidized with sodium periodate to generate alde-
hydes from the diols of the ribose at the cap structure
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and 3’-end, and these were biotinylated with biotin hydra-
zide (Vector Laboratories, Burlingame, CA, USA). The
remaining single-stranded RNA was digested with RNase
I (Promega, Madison, WI, USA) before capturing the bio-
tinylated cap structure with magnetic streptavidin beads
(Dynal Streptavidin M-270; Life Technologies, Carlsbad,
CA, USA). Single-stranded cDNA was recovered by heat
denaturation, and was ligated with the 3’-end and 5’-end
adaptors specific to the samples, subsequently. Double-
stranded cDNAs were prepared by using a primer and
DeepVent (exo−) DNA polymerase (New England,
Ipswich, MA, USA), and were mixed so that sequencing
with one lane could produce data from eight samples.
Three nanograms of the mixed samples were used to
prepare 120 μl of loading sample [15], which was loaded
on c-Bot, and sequenced by an Illumina HiSeq2500
sequencer (Illumina, San Diego, CA, USA).
Computational analysis of CAGE data to identify
candidate markers
The original samples from which individual reads were
obtained were identified with the ligated adaptor
sequences. After discarding reads including a base ‘N’ or
that hit a ribosomal RNA sequence (U13369.1) with
rRNAdust [16], the reads were aligned to the reference
genome (hg19) using BWA (version 0.7.10) [17], where
poorly aligned reads (mapping quality < 20) were dis-
carded using SAMtools (version 0.1.19) [18]. Only librar-
ies with more than two million mapped reads were used
for further analyses. The robust peak set [9] was used as
a reference set for TSS regions, and the number of
mapped reads starting from these regions were used as
raw signals for the promoter activities. Inactive TSS
regions, with counts per million (CPM) ≤ 1 in more than
77 % of the samples in both subtypes, were filtered out
[19], and 46,238 regions remained for the downstream
analysis. Multi-dimensional scaling (MDS) and differen-
tial analyses were conducted using the edgeR (version
2.6.7) [20] in R/bioconductor [21].
IHC
Four μm-thick tissue sections were prepared from
formalin-fixed paraffin-embedded blocks and subjected
to IHC. The antibodies used and their conditions are
described in Additional file 1: Table S1. IHC staining
was performed using an Envision Kit (Dako, Grostrup,
Denmark) with substrate-chromogen solution. A glass
slide was visually inspected and scored as follows for
novel markers identified by CAGE: score 0, no tumor
cells showing immunoreactivity; score 2, more than
50 % of tumor cells showing moderate or more severe
immunoreactivity; and score 1, not classified as score 0
or 2. Existing IHC markers, such as TTF-1, napsin A,
p40, cytokeratin (CK) 5, CK6, and desmoglein-3 (DSG3),
were scored as follows: score 0, no tumor cells showing
immunoreactivity; score 1, less than 10 % of tumor cells
showing immunoreactivity; and score 2, 10 % or more of
tumor cells showing immunoreactivity.
Scores of 0 and 1 were considered negative, and a score
of 2 was considered positive. The scoring was performed
by two independent pathologists (authors T.S. and K.H.)
without prior knowledge of the clinicopathological data,
and discrepancies were resolved by re-evaluation to reach
a consensus.
Clustering of tumors based on the IHC results
The distances between the samples with the IHC-based
marker expression patterns were calculated as Euclidean
distances for the positive/negative state, where the state
was assigned as 1 (positive) when the IHC score was 2,
and was assigned as 0 (negative) otherwise. The average
linkage clustering was performed independently on the
discovery set and validation sets, by using R (version
3.0.2, http://www.r-project.org/),
Results
Quantitative profiles of genome-wide promoter activities
in lung cancer
We obtained quantitative promoter activity profiles from
97 lung cancer tissues, consisting of 75 AD and 22 SCC,
using a CAGE protocol [7] with a next generation sequen-
cer (HiSeq2500). The two types of carcinoma are known
to show different expression patterns [22], which were
confirmed in our CAGE data (Fig. 1a). We also found that
several cases were not clearly separated, which is consist-
ent with previous studies using microarrays [22] or IHC
[23]. In particular, PDSCC and non-lepidic AD are diffi-
cult to be distinguished in the clinical setting when relying
on protein markers such as napsin A [24, 25] and TTF-1
[24, 25] (AD markers), or p40 [26, 27], DSG3 [24, 28],
CK5 [24, 25] and CK6 [25] (SCC markers).
SPATS2 and ST6GALNAC1 discriminate PDSCC and non-
lepidic AD
We focused on the two difficult to distinguish subtypes,
PDSCC and non-lepidic AD. Of 65 differentially expressed
promoters with (i) statistical significance (FDR < 0.01), (ii)
a high fold-change (>4-fold), and (iii) substantial expres-
sion (>4 cpm), 62 of them were highly expressed in
PDSCC and three were highly expressed in non-lepidic
AD (Fig. 1b, blue and red dots). We found that seven
promoters distinguished the subtypes completely after set-
ting a threshold, and we manually selected two promoters
corresponding to protein-coding genes: spermatogenesis
associated, serine-rich 2 (SPATS2) [29] and ST6 (alpha-N-
acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalacto
saminide alpha-2,6-sialyltransferase 1 (ST6GALNAC1)
[30], as candidate biomarkers (Fig. 1b, red dots).
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As shown in Fig. 2a, SPATS2 was active in SCC, par-
ticularly PDSCC, and less active in AD overall. Notably,
it was more active in PDSCC than differentiated SCC
(DSCC), which is unique for this molecule. In contrast,
ST6GALNAC1 was almost absent only in PDSCC
(<1 cpm; Fig. 2b). TTF-1, one of the known AD markers,
was absent in PDSCC, but was also often absent in some
of the non-lepidic AD cases. While napsin A is another
AD marker, it was often active in some of the PDSCC
cases. We found that both of SPATS2 and ST6GAL-
NAC1 showed unique expression patterns not found for
the known markers.
IHC identified the proteins of the candidate marker genes
in tumor tissues
We next examined the candidate biomarkers at the protein
level. We performed an IHC analysis on paraffin-embedded
tumors obtained from the same patients analyzed by CAGE
above, and found clear contrasts between the staining pat-
terns of SPATS2 and ST6GALNAC1 between AD and
SCC, even in the PD form of each tumor type (Fig. 3).
ST6GALNAC1 was more sensitive than TTF-1 in some
non-lepidic AD cases (Fig. 3f, h), and SPATS2 was more
sensitive than p40 in some PDSCC cases (Fig. 3n, o).
Notably, SPATS2 was localized to the cytoplasm of tumor
cells, although we also found positive staining at the basal
membrane of the alveolar septum and infiltrating plasma
cells. ST6GALNAC1 was localized on the cellular mem-
brane of tumor cells but also stained with bronchial
epithelium.
Significant contribution to discriminating the two subtypes
We then examined the performance of the new markers
in comparison with the existing markers by IHC. Paraffin-
embedded tumors obtained from the same patients used
in the CAGE analysis were immunostained for the six
known markers, as well as two novel marker candidates.
The heatmap showing the staining scores (Fig. 4a) indi-
cated that all of the markers were reasonably useful in
discriminating the two subtypes. Notably, SPATS2 and
ST6GALNAC1 were more sensitive for PDSCC and non-
lepidic AD (~66 %) than the existing markers respectively
when taking an IHC score of 2 as positive (Table 1).
Validation with an independent group of patients
confirmed the performance of the novel markers
We further assessed their performance of these markers
with an independent group of patients, consisting of 16
non-lepidic AD and 11 PDSCC. We confirmed the above
results, with the highest sensitivity and accuracy being for
a
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Fig. 1 Promoter activities in lung cancer. (a) An MDS plot. Similarities (distances) between individual carcinomas in the space of promoter activities (CAGE
profiles) are visualized in two dimensions by the multi-dimensional scaling implemented in the edgeR [20], where individual dots represent individual
carcinomas and similar carcinomas are plotted closely. The dot colors represent carcinoma subtypes as indicated in the legend, and the dotted line
indicates groups of carcinomas. (b) An MA-plot of the differential analysis between PDSCC and non-lepidic AD. The X-axis represents the average
expression levels in cpm, and the Y-axis represents the fold-changes in the log2 scale. Individual dots represent the activities of individual promoters, and
the blue dots indicate promoters with statistically significant differences (fold-change > 4, CPM> 4 and FDR < 0.01), and the red dots indicate the marker
candidates we selected
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these two markers (Table 2). We further expanded the val-
idation group by including seven cases of pure lepidic AD,
22 mixed lepidic AD, four WDSCC and 14 MDSCC
(in total, n = 74), and confirmed that ST6GALNAC1
had the highest sensitivity for detecting of any type of
AD (Additional file 1: Table S2). We also confirmed
the unique SPATS2 staining pattern, where a specific
subgroup of PDSCC (indicated by the arrowhead in
Fig. 4b) was not detectable without SPATS2.
Finally, we examined the results by assuming a defini-
tive diagnosis, rather than a diagnosis by exclusion.
Additional file 1: Table S3 indicates the results of the
definitive diagnosis using all combinations of a mini-
mum number (two) of molecular markers. It showed
that the combination of ST6GALNAC1 for AD and
CK5 for SCC provided a definitive diagnosis at the
highest accuracy, while some cases (n = 7, consisting of
two AD and five SCC cases) remained to be unclassifi-
able. The unclassifiable cases were further examined
(Additional file 1: Table S4), and we found that TTF-1 and
SPATS2 contributed to their successful classification. Both
of the novel markers are crucial for obtaining a definitive
diagnosis while avoiding inconclusive cases.
Discussion
The 2015 WHO Classification of Lung Tumors was re-
cently published [31]. IHC markers such as p40 and
TTF-1 are recommended for definitive histological diag-
nosis of SCC and AD when diagnosis is inconclusive
based solely on the morphological features, in order to
minimize the category NSCLC-not otherwise specified
or large cell carcinoma.
Several IHC markers have been used for subtyping
NSCLC. Most markers were identified without consider-
ation of the histological diversity in SCC and AD, which
makes their subtyping keep challenging in the clinical
settings. Diagnosing of DSCC and lepidic AD is straight-
forward morphologically, and IHC staining is not re-
quired for a diagnosis in most of these cases. Molecular
markers to discriminate subtypes that are difficult to
diagnose, such as PDSCC and non-lepidic AD, have a
high impact in the clinical settings. Therefore, we started
a
b
Fig. 2 Promoter activity levels of known markers and novel candidates. (a) The promoter activities of known markers for AD and the novel
candidate are shown in boxplots based on the carcinoma subtypes. (b) Equivalent boxplots for known markers of SCC and the candidate
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our analysis to identify marker candidates based on a
comparison of these subtypes.
Our genome-wide screening of promoter activities iden-
tified two marker candidates, SPATS2 as a PDSCC marker
and ST6GALNAC1 as a non-lepidic AD marker. Their
expression levels in individual histological subtypes sug-
gests that they will have utility in broadly discriminating
between SCC and AD, regardless of the histological diver-
sity. CAGE was somewhat effective in this screening step,
owing to its coverage of targets, namely all TSSs across
the genome, and its ability to quantify precise expression
levels. Although IHC is commonly used in clinical prac-
tice, its lack of these features makes it unsuitable for
screening. However, one of the drawbacks in transcrip-
tome analysis, including CAGE, of solid tissue is that the
profiling target consists of heterogenous cells. In the
present study, the profiled tissues likely consist of cancer
cells and normal pneumocytes. While the cancerous part
was obtained from a collection of samples, the resulting
data requires careful interpretation. We found the largest
variance in sample ranges from SCC to AD (Fig. 1), sug-
gesting that the ratio of normal pneumocytes was not very
different in the profiled tissues and has negligible impact
to the CAGE profile in comparison with the difference be-
tween DSCC and AD. We decided to perform further
examination based on IHC scores below, which clarify
whether the potential markers represent molecular states
of cancer cells or normal ones.
For a clinical diagnosis, IHC has been used more often
than RNA quantification. Therefore, we asked whether
the protein-level expression of these genes would also be
effective for obtaining a precise diagnosis. The staining
a b e f
c d g h
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Fig. 3 IHC for the novel marker candidates. A case of pure lepidic AD (a-d). H.E. staining (a) and IHC for TTF-1 (b), SPATS2 (c) and ST6GALNAC1
(d). The tumor cells are diffusely positive for ST6GALNAC1, but negative for TTF1 and SPATS2. A case of non-lepidic AD (e-h). H.E. staining (e) and
IHC for TTF-1 (f), SPATS2 (g) and ST6GALNAC1 (h). The tumor cells are diffusely positive for ST6GALNAC1, but negative for TTF1 and SPATS2. Note that
infiltrating plasma cells are also positive for SPATS2 (g). A case of WDSCC (i-l). H.E. staining (i) and IHC for p40 (j), SPATS2 (k) and ST6GALNAC1 (l). The
tumor cells are diffusely positive for SPATS2 and p40, but negative for ST6GALNAC1. A case of PDSCC (m-p). H.E. staining (m) and IHC for p40 (n), SPATS2
(o) and ST6GALNAC1 (p). The tumor cells are diffusely positive for SPATS2, but negative for p40 and ST6GALNAC1. Note that SPATS2 staining is more
sensitive than p40 staining. (original magnifications: x100, insets: x400)
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a b
Fig. 4 The results of IHC with the novel and known markers. (a) The presence of the known markers and the candidate markers was examined
by IHC of carcinoma tissues of non-lepidic AD and PDSCC obtained from the same patients evaluated in the CAGE analysis. The staining patterns
are scored (IHC score 0, 1, and 2) as described in the METHODS section, and the scores are visualized as heatmaps, where the tissues and markers
are clustered based on the IHC scores. (b) Equivalent heatmaps based on the results of an independent group of patients, consisting of pure lepidic
AD and mixed lepidic AD, DSCC, as well as non-lepidic AD and PDSCC
Table 1 Evaluation of the markers using the discovery set with 12 non-lepidic AD and three PDSCC patients
AD
markers
(Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) AD SCC AD SCC (95 % CI†) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
































(Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) SCC AD SCC AD (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)














































PPV Positive predictive value, NPV Negative predictive value, 95 % CI 95 % confidence interval, N.A Not available
†:95 % CIs of sensitivity, specificity, PPV, NPV and accuracy were estimated by the Clopper-Pearson method
* Novel biomarkers identified in the present study
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patterns with IHC were also clearly different for the sub-
types. The IHC scoring of the discovery set, the group of
tumors profiled by CAGE, demonstrated high sensitiv-
ities as discrimination markers (Fig. 4a, Table 1). These
results not only validated the findings for the RNA ex-
pression, but also demonstrated that these genes can be
used as biomarkers at either the mRNA or protein level.
Finally, we examined their diagnostic utility by using
an independent set of 74 cases by IHC. ST6GALNAC1
showed higher sensitivity and accuracy than the existing
IHC markers for AD, such as TTF-1 and napsin A. In
contrast, SPATS2 showed a unique staining pattern,
where it was positive in SCC cases, even when the stain-
ing results of the existing SCC markers (p40, DSG3,
CK5 and CK6) were negative (Fig. 4b, Additional file 1:
Table S2). All of these results are consistent with those
of the discovery set, and confirmed their performance as
their diagnosis markers in another set of tumors.
We subsequently examined the potential of these
markers for obtaining a definitive diagnosis. A combin-
ation of ST6GALNAC1 for AD and CK5 for SCC had
the best performance (90.5 % accuracy), while a few
cases remained as inconclusive (9.5 %) (Additional file 1:
Table S3). Within the inconclusive cases, a combination
of TTF-1 for AD and SPATS2 for SCC provided the best
performance (100 % accuracy) (Additional file 1: Table
S4). In contrast, the combination of TTF-1 and p40,
broadly considered to be most reliable for the differential
diagnosis between SCC and AD [27, 32, 33], showed an
accuracy of 77 % in our study population. These results
demonstrate that the two novel makers are effective in
combination with some known markers for obtaining a
definitive diagnosis. A promising approach for definitive
diagnosis is to perform IHC on both ST6GALNAC1 and
CK5 at the first step, and then to examine both TTF-1
and SPATS2 only when the results of the first step are
inconclusive.
ST6GALNAC1 is a member of the sialyltransferase fam-
ily of molecules, which was reported as overexpressed in
several cancers, including gastric cancer, and as correlated
with cancer metastasis. Notably, hypomethylation at 2 bp
upstream of its TSS was reported in diseases such as es-
trogen and progesterone receptor-negative breast cancers
[34], schizophrenia, and bipolar disorder [35]. SPATS2
was reported to play a critical role in spermatogenesis and
development of testicular germ cell [36], and no reports
on diseases association except for recent study on, its
paralog, SPATS2L , in a context of bronchodilator re-
sponse gene with a genome-wide association study [37].
Further studies are required to elucidate the roles of the
novel markers in lung cancer.
Several limitations to using SPATS2 and ST6GAL-
NAC1 as IHC markers in clinical use warrant mention.
First, localizations of immunostaining are not limited to
the nucleus of tumor cells. IHC staining of only the
tumor nucleus is ideal because passive diffusion of non-
nuclear markers is observed using small or crushed sam-
ples. However, SPATS2 was localized to the cytoplasm of
Table 2 Evaluation of the markers using the validation set with 16 non-lepidic AD and 11 PDSCC patients
AD markers (Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) AD SCC AD SCC (95 % CI†) (95 % CI) (95 % CI) (95 % CI) (95 % CI)






























SCC markers (Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) SCC AD SCC AD (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)


















































PPV Positive predictive value, NPV Negative predictive value, 95 % CI 95 % confidence interval
†: 95 % CIs of sensitivity, specificity, PPV, NPV and accuracy were estimated by the Clopper-Pearson method
* Novel biomarkers identified in the present study
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tumor cells but also stained the basal membrane of the
alveolar septum and infiltrating plasma cells. ST6GAL-
NAC1 was localized on the cellular membrane of tumor
cells but also stained the bronchial epithelium. Second,
proportions of score 1 for SPATS2 and ST6GALNAC1
were higher than for other existing IHC markers because
the tentative diagnostic criteria for the novel IHC
markers were used. Namely, only cases in which more
than 50 % of tumor cells showed moderate or more
severe immunoreactivity were considered positive, to
reduce the rate of false positive results with antibodies
not optimized for clinical diagnosis. To our knowledge,
no optimized scoring system or optimized antibodies for
novel IHC markers using a large number of surgical
specimens have been established. Third, this study was
performed based on only the surgical specimens. There-
fore, further prospective studies based on cytology or
small biopsy samples need to be conducted to confirm
the utility of novel markers in these clinically meaningful
setting.
Conclusions
We discovered novel biomarkers, ST6GALNAC1 and
SPATS2, which assist in accurate discrimination between
SCC and AD. We demonstrated that these markers
contributed to successful subtyping, even in cases where
morphological discrimination was difficult, such as PDSCC
and non-lepidic AD. We found that the majority of SCC
and AD cases are distinguishable using a combination of
ST6GALNAC1 and CK5, while the remaining cases can be
distinguished using the combination of TTF-1 and SPATS2.
These findings shed light on a new way to accurately
subtype NSCLC, contributing to precision medicine for
lung cancer.
Additional file
Additional file 1: Table S1. The immunohistochemical staing conditions
and antibodies used in this study. Table S2. Evaluation of the markers using
the validation set with 45 AD and 29 SCC patients. Table S3. Classification of
AD and SCC by combinations of AD and SCC markers. Table S4. Evaluation of
the markers for seven unclassifiable patients showing ST6GALNAC1(-)/CK5(-) or
ST6GALNAC1(+)/CK5(+). (DOCX 53 kb)
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